# Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis

> **NCT01258309** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 129 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal
- Conjunctivitis, Allergic

## Interventions

- **DRUG:** olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution
- **DRUG:** olopatadine hydrochloride 0.1% ophthalmic solution

## Key facts

- **NCT ID:** NCT01258309
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2012-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01258309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01258309, "Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01258309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*